Therapy Areas: Cardiovascular
Arrowhead earns USD20m milestone payment from Amgen
29 July 2020 -

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR), a developer of RNAi-based therapeutics, has earned a USD20m milestone payment under its agreement with biopharmaceutical company Amgen Inc (NASDAQ:AMGN), Arrowhead said on Wednesday.

The payment was triggered after the first dose of AMG 890, formerly referred to as ARO-LPA, was administered in a Phase 2 clinical study. This study is evaluating the efficacy, safety and tolerability of AMG 890 in subjects with elevated levels of lipoprotein (a), or Lp(a). Elevated levels of Lp(a) are strongly associated with cardiovascular disease.

AMG 890 is an investigational RNA interference (RNAi) therapeutic designed to lower Lp(a) for the treatment of cardiovascular disease.

Under the terms of the agreement with Amgen, which was announced in September 2016, Arrowhead is eligible to receive development, regulatory and sales milestone payments as well as up to low double-digit royalties on sales of resulting products.



Related Headlines